Exscientia PLC (EXAI) Börsenkurse

Form 15-12G - Securities registration termination [Section 12(g)]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi

Les deux programmes démontrent la capacité d’Exscientia à concevoir des molécules hautement différenciées et qui ont le potentiel de devenir les...